![Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition](https://www.frontiersin.org/files/Articles/610903/fcell-08-610903-HTML/image_m/fcell-08-610903-g001.jpg)
Frontiers | The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
![Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species | Drug Metabolism & Disposition Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/sites/default/files/highwire/dmd/50/3.cover-source.jpg)
Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species | Drug Metabolism & Disposition
![Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01908-1/MediaObjects/41416_2022_1908_Fig1_HTML.png)
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing | British Journal of Cancer
Pyrazolate-Based Porphyrinic Metal–Organic Framework with Extraordinary Base-Resistance | Journal of the American Chemical Society
Computational Studies of CO2 Sorption and Separation in an Ultramicroporous Metal–Organic Material | The Journal of Physical Chemistry C
![Biomolecules | Free Full-Text | Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma Biomolecules | Free Full-Text | Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma](https://www.mdpi.com/biomolecules/biomolecules-12-01562/article_deploy/html/images/biomolecules-12-01562-g001.png)
Biomolecules | Free Full-Text | Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
![Current Oncology | Free Full-Text | New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer Current Oncology | Free Full-Text | New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer](https://www.mdpi.com/curroncol/curroncol-29-00004/article_deploy/html/images/curroncol-29-00004-g001.png)
Current Oncology | Free Full-Text | New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer
![Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ... Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ...](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2022/po.2022.6/po.21.00446/20220812/images/keyimage.jpg)
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After ...
![Frontiers | Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments Frontiers | Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments](https://www.frontiersin.org/files/Articles/912699/fonc-12-912699-HTML/image_m/fonc-12-912699-g001.jpg)
Frontiers | Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
![Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response - Rawding - 2022 - WIREs Nanomedicine and Nanobiotechnology - Wiley Online Library Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response - Rawding - 2022 - WIREs Nanomedicine and Nanobiotechnology - Wiley Online Library](https://wires.onlinelibrary.wiley.com/cms/asset/3d2f75da-98eb-4314-a642-aedda9742051/wnan1752-toc-0001-m.jpg)
Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response - Rawding - 2022 - WIREs Nanomedicine and Nanobiotechnology - Wiley Online Library
Stable Metal–Organic Frameworks with Group 4 Metals: Current Status and Trends | ACS Central Science
![JPM | Free Full-Text | Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma JPM | Free Full-Text | Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma](https://www.mdpi.com/jpm/jpm-11-01324/article_deploy/html/images/jpm-11-01324-g001.png)